Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
5
71%
Ph phase_1
2
29%

Phase Distribution

2

Early Stage

5

Mid Stage

0

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
2(28.6%)
Phase 2Efficacy & side effects
5(71.4%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(5)
Terminated(2)

Detailed Status

Completed5
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
83.3%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (28.6%)
Phase 25 (71.4%)

Trials by Status

terminated114%
completed571%
withdrawn114%

Recent Activity

0 active trials
Showing 5 of 7
withdrawnphase_1

Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

NCT03228940
completedphase_2

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

NCT01058018
completedphase_1

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

NCT00768274
terminatedphase_2

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

NCT01863225
completedphase_2

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

NCT01728467
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT03228940Phase 1

Safety and Effect of Oral RVX000222 in Subjects With Fabry Disease

Withdrawn
NCT01058018Phase 2

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Completed
NCT00768274Phase 1

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Completed
NCT01863225Phase 2

Characterization of Multi-dose RVX000222 in Combination With Statin Treatment in Dyslipidemia

Terminated
NCT01728467Phase 2

The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes

Completed
NCT01067820Phase 2

ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation

Completed
NCT01423188Phase 2

The Study of Quantitative Serial Trends in Lipids With ApolpoproteinA-I Stimulation

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7